Drug
Ft819
Ft819: highest development phase Phase 2, developed by Fate Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Fate Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| FT819 NCT07570862 | Phase 2 | Lupus Nephritis |
| FT819 NCT06308978 | Phase 1 | Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV) |
| FT819 NCT04629729 | Phase 1 | Lymphoma, B-Cell |
Latest
No recent events.
Follow Ft819 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.